ARVINAS, INC. Cash and Restricted Cash
ARVINAS, INC. (ARVN) had Cash and Restricted Cash of $94.30 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $94.30M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $87.30M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $142.90M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $101.50M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $94.30M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $87.30M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $142.90M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $101.50M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $114.90M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $81.00M 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $100.50M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $85.20M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $160.30M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $93.50M 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $317.20M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $119.20M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $96.10M 10-Q · filed 2024-07-30 | |
| 2023-03-31 | $135.70M 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $86.80M 10-K · filed 2026-02-24 | |
| 2022-09-30 | $138.10M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $97.70M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $66.80M 10-Q · filed 2023-05-05 | |
| 2021-12-31 | $112.80M 10-K · filed 2025-02-11 | |
| 2021-09-30 | $260.20M 10-Q · filed 2022-11-09 | $260.16M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $53.20M 10-Q · filed 2022-08-04 | $53.23M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $346.10M 10-Q · filed 2022-05-05 | $346.07M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $588.40M 10-K · filed 2024-02-27 | $588.37M 10-K · filed 2021-03-01 |
| 2020-09-30 | $88.99M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $21.59M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $36.11M 10-Q · filed 2021-05-04 | |
| 2019-12-31 | $9.20M 10-K · filed 2023-02-23 | $9.21M 10-K · filed 2020-03-16 |
| 2019-09-30 | $12.14M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $11.34M 10-Q · filed 2020-08-04 | |
| 2019-03-31 | $28.79M 10-Q · filed 2020-04-28 | |
| 2018-12-31 | $3.20M 10-K · filed 2022-02-28 | $3.19M 10-K · filed 2019-03-26 |
| 2018-09-30 | $6.19M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $3.35M 10-Q · filed 2019-08-05 | |
| 2018-03-31 | $60.83M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $30.91M 10-K · filed 2021-03-01 | |
| 2017-09-30 | $2.46M 10-Q · filed 2018-11-14 | |
| 2016-12-31 | $5.09M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |